Partalidou Styliani, Patoulias Dimitrios, Pantekidis Ioannis, Kefas Aristeidis, Doumas Michael, Gkaliagkousi Eugenia, Rizzo Manfredi, Dimitroulas Theodoros, Anyfanti Panagiota
First Department of Internal Medicine, 424 General Military Hospital of Thessaloniki, Thessaloniki, Greece.
2nd Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
J Diabetes Metab Disord. 2025 Jun 9;24(2):144. doi: 10.1007/s40200-025-01647-z. eCollection 2025 Dec.
Arterial stiffness (AS) is a well-established index of macrovascular damage and predicts cardiovascular complications in many diseases including diabetes mellitus (DM). DM is strongly linked with microcirculatory changes, including retinopathy, microalbuminuria and neuropathy. We aimed to review in a systematic manner the possible correlation between AS and microvascular impairment in patients with DM, type 1 or 2. We performed a systematic literature search in PubMed, Scopus and Embase database. We included studies evaluating the correlation of AS and impaired microcirculation in adult patients with type 1 or 2 DM. AS could be evaluated with pulse wave velocity, carotid-ankle vascular index, ambulatory arterial stiffness index and augmentation index. Impaired microcirculation was defined by the presence of one or more of the following: retinopathy, albuminuria, neuropathy, dermal capillary alterations. We eventually included 51 studies in our systematic review. Data were extracted by two investigators and were critically appraised with ROBINS-I tool of Cochrane Library for non-randomized trials. The majority of studies have demonstrated positive correlation between AS and microvascular impairment, usually in a dose-response association. However, most studies have focused on the association of AS with retinopathy, whereas the association with dermal microvascular alterations remains scarcely investigated. Disease duration was underlined by most authors as an independent predictor of increased AS. These findings suggest that AS should be sought upon detection of microvascular complications in patients with T1DM or T2DM; vice versa, patients with T1DM or T2DM with increased levels of AS should be screened for microvascular alterations.
动脉僵硬度(AS)是一个公认的大血管损伤指标,可预测包括糖尿病(DM)在内的多种疾病的心血管并发症。DM与微循环变化密切相关,包括视网膜病变、微量白蛋白尿和神经病变。我们旨在系统回顾1型或2型糖尿病患者中AS与微血管损伤之间可能存在的相关性。我们在PubMed、Scopus和Embase数据库中进行了系统的文献检索。我们纳入了评估1型或2型成年糖尿病患者AS与微循环受损相关性的研究。AS可以通过脉搏波速度、颈-踝血管指数、动态动脉僵硬度指数和增强指数来评估。微循环受损的定义为存在以下一种或多种情况:视网膜病变、蛋白尿、神经病变、皮肤毛细血管改变。我们最终在系统评价中纳入了51项研究。数据由两名研究人员提取,并用Cochrane图书馆的ROBINS-I工具对非随机试验进行严格评估。大多数研究表明AS与微血管损伤之间存在正相关,通常呈剂量反应关系。然而,大多数研究集中在AS与视网膜病变的关联上,而与皮肤微血管改变的关联仍鲜有研究。大多数作者强调病程是AS增加的独立预测因素。这些发现表明,在1型糖尿病或2型糖尿病患者检测到微血管并发症时应检查AS;反之,AS水平升高的1型糖尿病或2型糖尿病患者应筛查微血管改变。